Eton Pharmaceuticals’ Post

We are excited to announce that Eton Pharmaceuticals has successfully completed the acquisition of Increlex® (mecasermin injection). This transformative addition to our pediatric endocrinology portfolio reinforces our commitment to advancing care for rare diseases. Read the full press release here: https://lnkd.in/gV9dYYn8. We are proud to continue providing this essential treatment and look forward to collaborating with healthcare professionals and the patient and caregiver community. This content is intended for informational purposes only. Full U.S. Prescribing Information for Increlex® is available at: https://lnkd.in/gWgKKApQ. #PatientFirst #PediatricEndocrinology #RareDiseases #Increlex #EtonPharmaceuticals #PressRelease